# Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery

> **NCT01234532** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 5 (actual)

## Conditions studied

- Estrogen Receptor-negative Breast Cancer
- HER2-negative Breast Cancer
- Progesterone Receptor-negative Breast Cancer
- Stage I Breast Cancer
- Stage II Breast Cancer
- Stage IIIA Breast Cancer
- Triple-negative Breast Cancer

## Interventions

- **DRUG:** entinostat
- **DRUG:** anastrozole
- **OTHER:** diagnostic laboratory biomarker analysis
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT01234532
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2017-05
- **Final completion:** 2017-05
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01234532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01234532, "Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01234532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*